Full-Time

Manager – AI&D Engagement and Go-to-Market

GTM

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$126.4k - $154.7k/yr

+ Bonus + Stock-based long-term incentives

Senior, Expert

Remote in USA

Category
Applied Machine Learning
Natural Language Processing (NLP)
AI & Machine Learning
Required Skills
Product Management
Marketing
Requirements
  • Doctorate degree
  • OR Master’s degree and 2 years of AI or technology education or Go-to-Market experience
  • OR Bachelor’s degree and 4 years of AI or technology education or Go-to-Market experience
  • OR Associate’s degree and 8 years of AI or technology education or Go-to-Market experience
  • OR High school diploma / GED and 10 years of AI or technology education or Go-to-Market experience
Responsibilities
  • Plan and deliver AI literacy initiatives across Amgen, with an initial focus on senior leaders
  • Establish a culture of AI readiness and continuous learning across the organization
  • Collaborate with product, technology, and product teams to plan, coordinate and implement AI literacy events
  • Create cultural transformation communication material for engagement strategies that drive organizational alignment on AI initiatives
  • Ensure successful product launches by coordinating efforts between teams to increase adoption and return on investment impact
  • Implement tailored education programs to build AI fluency across all levels of the organization, ensuring teams are equipped to use AI effectively. Develop tailored material and training modules for leaders partners
  • Organize and deliver high-impact events (e.g., AI Symposiums, Demo Days, Hackathons) to foster community engagement. Create marketing material and campaigns for these events.
  • Lead the delivery of comprehensive go-to-market for AI&D products. Partner with leadership across technical product, ATMOS, HR, and corporate teams to plan and implement GTM initiatives.
  • Coordinate with product teams to enable successful product adoption and growth, providing necessary resources, training, and messaging.
  • Create material to ensure cohesive messaging and clear articulation of AI's value across the organization
  • Track and report on the effectiveness of education programs and GTM initiatives. Create measurement capabilities to continuously measure KPIs and success metrics for GTM initiatives and ensure continuous performance monitoring.
Desired Qualifications
  • 5+ years of experience in community engagement, technology education, or GTM strategy roles
  • Consistent track record of executing successful education or GTM technology programs, preferably in a biopharma, technology, or AI-focused environment
  • Demonstrable ability to translate technical concepts for non-technical stakeholders and communicate effectively to both technical and non-technical audiences
  • Excellent project management skills with a record of building strong partnerships across cross-functional teams and managing diverse workloads to meet deadlines
  • Ability to work autonomously with minimal guidance and know when to seek input, combined with a collaborative approach to obtain alignment and support project goals
  • Understanding of AI-focused solutions and digital transformation trends, particularly in life sciences
  • Strong leadership and team management skills with experience managing cross-functional teams for GTM and technical education programs
  • Solid understanding of AI technologies and trends, with the ability to translate technical concepts into business value
  • Familiarity with AI&D product lifecycle and go-to-market strategies

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen stands out from competitors by reinvesting a large portion of its earnings into research and development, ensuring a strong pipeline of new treatments. The goal of Amgen is to improve patient care and address critical health challenges through its innovative therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.